Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Average Price Target of $48.71 According to Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $48.71.

Several analysts have recently commented on the company. Needham & Company LLC decreased their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Oppenheimer began coverage on Collegium Pharmaceutical in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 target price on the stock. Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Finally, Leerink Partners started coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target for the company.

Collegium Pharmaceutical Trading Down 0.8%

NASDAQ COLL opened at $23.01 on Tuesday. Collegium Pharmaceutical has a 52 week low of $21.43 and a 52 week high of $50.79. The company has a 50 day moving average price of $23.99 and a 200 day moving average price of $30.76. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The firm has a market cap of $749.21 million, a PE ratio of 3.32, a price-to-earnings-growth ratio of 0.72 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same period last year, the firm earned $1.68 earnings per share. Collegium Pharmaceutical’s revenue was up 6.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 6.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd boosted its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the last quarter. Assetmark Inc. grew its position in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares during the last quarter. Allworth Financial LP acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at approximately $175,000. Finally, EverSource Wealth Advisors LLC increased its stake in Collegium Pharmaceutical by 20.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock valued at $167,000 after purchasing an additional 861 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.